Recommendations on the use of biosimilars by the Brazilian Society of Rheumatology, Brazilian Society of Dermatology, Brazilian Federation of Gastroenterology and Brazilian Study Group on Inflammatory Bowel Disease-Focus on clinical evaluation of monoclonal antibodies and fusion proteins used in the treatment of autoimmune diseases

Autoimmunity Reviews

Volumn 14, Issue 9, 2015, Pages 769-773

  Azevedo, Valderílio Feijó ^a   de Souza Meirelles, Eduardo ^a   Kochen, Jussara de Almeida Lima ^a   Medeiros, Ana Cristina ^a   Miszputen, Sender J ^c,d   Teixeira, Fábio Vieira ^d   Damião, Adérson Osmar Mourão Cintra ^d   Kotze, Paulo Gustavo ^d   Romiti, Ricardo ^b   Arnone, Marcelo ^b   Ferreira Magalhães, Renata ^b   Maia, Cláudia Pires Amaral ^b   de Carvalho, André Vicente E ^b  

^a Brazilian Society of Rheumatology   (Brazil)

^b Brazilian Society of Dermatology   (Brazil)

^c Brazilian Federation of Gastroenterology   (Brazil)

^d Brazilian Study Group on Inflammatory Bowel Disease   (Brazil)

Author keywords

Ankylosing spondylitis; Autoimmune diseases; Biosimilars; Crohn's disease; Psoriasis; Rheumatoid arthritis

Indexed keywords

BIOSIMILAR AGENT; HYBRID PROTEIN; MONOCLONAL ANTIBODY; RECOMBINANT PROTEIN;

ANKYLOSING SPONDYLITIS; AUTOIMMUNE DISEASE; CLINICAL EVALUATION; CLINICAL STUDY; CROHN DISEASE; DERMATOLOGY; DRUG INDICATION; DRUG MANUFACTURE; DRUG MARKETING; DRUG SURVEILLANCE PROGRAM; GASTROENTEROLOGY; HUMAN; INFLAMMATORY BOWEL DISEASE; JUVENILE RHEUMATOID ARTHRITIS; MEDICAL SOCIETY; MEDICAL SPECIALIST; NOMENCLATURE; PHARMACEUTICAL CARE; PRACTICE GUIDELINE; PRESCRIPTION; PSORIATIC ARTHRITIS; REVIEW; RHEUMATOID ARTHRITIS; RHEUMATOLOGY; ULCERATIVE COLITIS; ANIMAL; AUTOIMMUNE DISEASES; BRAZIL; GASTROINTESTINAL DISEASES;

ANIMALS; ANTIBODIES, MONOCLONAL; AUTOIMMUNE DISEASES; BIOSIMILAR PHARMACEUTICALS; BRAZIL; GASTROINTESTINAL DISEASES; HUMANS; RECOMBINANT PROTEINS; SOCIETIES, MEDICAL;

EID: 84938205217     PISSN: 15689972     EISSN: 18730183     Source Type: Journal    
DOI: 10.1016/j.autrev.2015.04.014     Document Type: Review

References (44)

1. Kozlowski S., Woodcock J., Midthun K., Sherman R.B. Developing the nation's biosimilars program. N Engl J Med 2011, 365:385-388.
2. Schiestl M. A biosimilar industry view on the implementation of the WHO guidelines on evaluating similar biotherapeutic products. Biologicals 2011, 39:297-299.
3. Roger S.D. Biosimilars: current status and future directions. Expert Opin Biol Ther 2010, 10:1011-1018.
4. Kresse G.B. Biosimilars-science, status, and strategic perspective. Eur J Pharm Biopharm 2009, 72:479-486.
5. Wiens A., Venson R., Correr C.J., Otuki M.F., Pontarolo R. Meta-analysis of the efficacy and safety of adalimumab, etanercept, and infliximab for the treatment of rheumatoid arthritis. Pharmacotherapy 2010, 30:339-353.
6. Bansback N., Sizto S., Sun H., Feldman S., Willian M.K., Anis A. Efficacy of systemic treatments for moderate to severe plaque psoriasis: systematic review and meta-analysis. Dermatology 2009, 219:209-218.
7. Peyrin-Biroulet L., Deltenre P., de Suray N., Branche J., Sandborn W.J., Colombel J.F. Efficacy and safety of tumor necrosis factor antagonists in Crohn's disease: meta-analysis of placebo-controlled trials. Clin Gastroenterol Hepatol 2008, 6:644-653.
8. Leonardi C.L., Romiti R., Tebbey P.W. Ten years on: the impact of biologics on the practice of dermatology. Dermatol Clin 2015, 33:111-125.
9. Chevreul K., Haour G., Lucier S., Harvard S., Laroche M.-L., Mariette X., et al. Evolution of direct costs in the first years of rheumatoid arthritis: impact of early versus late biologic initiation-an economic analysis based on the ESPOIR cohort. PLoS One 2014, 9:e97077. [Available at:2014 May 8].
10. Azevedo V.F. Are we prepared to prescribe biosimilars?. Rev Bras Reumatol 2010, 50:221-224.
11. Strober B.E., Armour K., Romiti R., Smith C., Tebbey P.W., Menter A., et al. Biopharmaceuticals and biosimilars in psoriasis: what the dermatologist needs to know. J Am Acad Dermatol 2012, 66:317-322.
12. Food and Drug Administration Available at, [Accessed February 13]. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM291128.pdf.
13. Azevedo V.F., Mysler E., Álvarez A.A., Hughes J., Flores-Murrieta F.J., de Castilla E.M.R. Recommendations for the regulation of biosimilars and their implementation in Latin America. GaBI J 2014, 3:143-148.
14. Schneider C.K., Borg J.J., Ehmann F., Ekman N., Heinonen E., Ho K., et al. In support of the European Union biosimilar framework. Nat Biotechnol 2012, 30:745-748.
15. Minghetti P., Rocco P., Cilurzo F., Del Vecchio L.D., Locatelli F. The regulatory framework of biosimilars in the European Union. Drug Discov Today 2012, 17:63-70.
16. European Medicines Agency Guideline on similar biological medicinal products containing monoclonal antibodies-non-clinical and clinical issues Available at, [Accessed July 16]. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2012/06/WC500128686.pdf2012.
17. Simoens S., Verbeken G., Huys I. Biosimilars and market access: a question of comparability and costs?. Target Oncol 2012, 7:227-231.
18. World Health Organization Executive summary. 55th Consultation on International nonproprietary names for pharmaceutical substances, Geneva, 16-18 October 2012. INN Working Doc. 13.329, World Health Organization Available at, [Accessed February 13 2015]. http://www.who.int/medicines/services/inn/55th_Executive_Summary.pdf.
19. Pineda C., Caballero-Uribe C.V., de Oliveira M.G., Lipszyc P.S., Lopez J.J., Mataos Moreira M.M., et al. Recommendations on how to ensure the safety and effectiveness of biosimilars in Latin America: a point of view. Clin Rheumatol 2015 Apr 34, 4:635-640.
20. Casadevall N., Edwards I.R., Felix T., Graze P.R., Litten J.B., Strober B.E., et al. Pharmacovigilance and biosimilars: considerations, needs and challenges. Expert Opin Biol Ther 2013, 13:1039-1047.
21. Azevedo V.F. Biosimilars require scientifically reliable comparative clinical data. Rev Bras Reumatol 2013, 53:129-131.
22. Pinto V.F. Non-inferiority clinical trials: concepts and issues. J Vasc Bras 2010, 9:145-151.
23. Fletcher M.P. Biosimilars clinical development program: confirmatory clinical trials: a virtual/simulated case study comparing equivalence and non-inferiority approaches. Biologicals 2011, 39:270-277.
24. Park W., Hrycaj P., Jeka S., Kovalenko V., Lysenko G., Miranda P., et al. A randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: the PLANETAS study. Ann Rheum Dis 2013, 72:1605-1612.
25. Yoo D.H., Hrycaj P., Miranda P., Ramiterre E., Piotrowski M., Shevchuk S., et al. A randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: the PLANETRA study. Ann Rheum Dis 2013, 72:1613-1620.
26. Dörner T., Strand V., Castañeda-Hernández G., Ferraccioli G., Isaacs J.D., Kvien T.K., et al. The role of biosimilars in the treatment of rheumatic diseases. Ann Rheum Dis 2013, 72:322-328.
27. Fonseca J.E., Gonçalves J., Araújo F., Cordeiro I., Teixeira F., Canhão H., et al. The Portuguese Society of Rheumatology position paper on the use of biosimilars. Acta Reumatol Port 2014, 39:60-71.
28. Saavedra S.I., Quiñones S.L. Considerations about the approval of biosimilar formulations (biogenerics) in Chile. [Interchangeability of biological drugs: considerations about the approval of biogeneric formulations in Chile]. Rev Med Chil 2006, 134:1583-1588.
29. Food and Drug Administration Available at, [Accessed February 14]. http://www.fda.gov/downloads/Drugs/Guidances/UCM273001.pdf.
30. Agência Nacional de Vigilância Sanitária Available at, [Accessed February 14]. http://portal.anvisa.gov.br/wps/content/Anvisa.
31. Azevedo V.F., Mysler E., Álvarez A.A., Hughes J., Flores-Murrieta F.J., Ruiz de Castilla E.M.R. Recommendations for the regulation of biosimilars and their implementation in Latin America. GAbi J 2014, 3:143-148.
32. Beck A., Reichert J.M. Approval of the first biosimilar antibodies in Europe: a major landmark for the biopharmaceutical industry. MAbs 2013, 5:621-623.
33. Scott B.J., Klein A.V., Wang J. Biosimilar monoclonal antibodies: a Canadian regulatory perspective on the assessment of clinically relevant differences and indication extrapolation. J Clin Pharmacol 2014, [Epub ahead of print]. 10.1002/jcph.339.
34. Feagan B.G., Choquette D., Ghosh S., Gladman D.D., Ho V., Meibohm B., et al. The challenge of indication extrapolation for infliximab biosimilars. Biologicals 2014, 42:177-183.
35. Lee H. Is extrapolation of the safety and efficacy data in one indication to another appropriate for biosimilars?. AAPS J Jan 2014, 16:22-26.
36. Ebbers H.C. Biosimilars: in support of extrapolation of indications. J Crohns Colitis 2014, 8:431-435.
37. Scheinberg M. Biosimilars in Crohn's disease. J Crohns Colitis 2014, 8:710.
38. Ghosh S. Subsequent entry biologics-opportunities and challenges. Can J Gastroenterol 2013, 27:565.
39. Gecse K.B., Khanna R., van den Brink G.R., Ponsioen C.Y., Lowenberg M., Jairath V., et al. Biosimilars in IBD: hope or expectation?. Gut 2013, 62:803-807.
40. Billiet T., Rutgeerts P., Ferrante M., Van Assche G., Vermeire S. Targeting TNFalpha for the treatment of inflammatory bowel disease. Expert Opin Biol Ther 2014, 14:75-101.
41. Danese S., Gomollon F. Governing Board and Operational Board of ECCO. ECCO position statement: the use of biosimilar medicines in the treatment of inflammatory bowel disease (IBD). J Crohns Colitis 2013, 7:586-589.
42. Devlin S.M., Bressler B., Bernstein C.N., Fedorak R.N., Bitton A., Singh H., et al. Overview of subsequent entry biologics for the management of inflammatory bowel disease and Canadian Association of Gastroenterology position statement on subsequent entry biologics. Can J Gastroenterol 2013, 27:567e71.
43. TITTON, David C. Registro brasileiro de biológicos: processo de implementação e resultados preliminares do BiobadaBrasil. Rev Bras Reumatol 2011, 51:152-160. [online].
44. Mendes de Abreu M., Strand V., Levy R.A., Araujo D.V. Putting the value into biosimilar decision making: the judgment value criteria. Autoimmun Rev 2014, 13:678-684.